-
Article
Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy
Immune checkpoint blockade therapy has become a first-line treatment in various cancers. But there are only a small percent of colorectal patients responding to PD-1/PD-L1 blockage immunotherapy. How to increa...
-
Article
Open AccessPublisher Correction: ‘TRAIL-based gene delivery and therapeutic strategies’ and ‘Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy’
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Open AccessOverview of recent advances in liposomal nanoparticle-based cancer immunotherapy
The clinical performance of conventional cancer therapy approaches (surgery, radiotherapy, and chemotherapy) has been challenged by tumor metastasis and recurrence that is mainly responsible for cancer-caused ...
-
Article
Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy
Multidrug resistance (MDR) is a major hurdle in cancer chemotherapy and makes the treatment benefits unsustainable. Combination therapy is a commonly used method for overcoming MDR. In this study we investigat...
